Clinical trials: Transplant Failure
Kidney Transplant Failure and Rejection, Immunosuppression
Long-term Outcomes After Conversion to Belatacept
belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients.
- Conditions
- Kidney Transplant Failure and Rejection, Immunosuppression, Graft Loss, Drug Effect Prolonged
- Trial name
- NCT04733131
- Testing
- Conversion to a belatacept regimen
- Volunteers
- 324 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
End Stage Liver Disease, Hepatitis C
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03208127
- Testing
- Treatment with Direct Acting Antiviral tablet
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma Non-resectable
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
Currently in France, hepatocellular carcinoma (HCC) represents over 30% of indications of liver transplantation (LT) (# 500 cases/year).
- Trial name
- Ta-Len-Tra (NCT05901194)
- Testing
- Lenvatinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Diseases, End Stage Liver Disease
Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation
This is a single center, 2-arm, patient-randomized study evaluating the feasibility and potential efficacy of the PRIMER intervention in improving physical function and reducing frailty in adult Liver Transplant candidates.
- Conditions
- Liver Diseases, End Stage Liver Disease, Frailty
- Trial name
- PRIMER (NCT03584646)
- Testing
- Nokia GO Wearable StepTracker, Medication Reminder, Weekly Check-in appointment with study team or provider
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Leukemia, Graft Failure
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
Poor graft function (PGF) after allogeneic hematopoietic cell transplantation (allo-HCT) is a misunderstood complication associated with poor outcome and limited therapeutic options.
- Trial name
- REGALIA (NCT03948529)
- Testing
- eltrombopag
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Lille
Kidney Transplant Failure and Rejection
BIOtechnology Applied to Renal TRansplantation With IMmunobiogram
Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients…
- Trial name
- BIOTRAIM (NCT05816486)
- Testing
- Immunobiogram
- Where
- 15 sites in Brazil, France and 3 more
- Volunteers
- 443 people
- Sponsor
- Biohope Scientific Solutions for Human Health, S.L.
Kidney Failure, Hypertension
Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation
A reduce in renal mass may result in remnant single nephron hyperfiltration, with associated proteinuria and an accelerated loss of kidney function.
- Conditions
- Kidney Failure, Hypertension, Albuminuria, Renal Failure
- Trial name
- NCT01564966
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Istanbul University
End-stage Renal Disease, Dialysis
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
1600 patients with severe, end stage renal disease or post transplant will be randomised 1:1:1 to either standard therapeutic education; or education using a specific app; or the enhanced interactive app using feedback messages.
- Conditions
- End-stage Renal Disease, Dialysis, Kidney Transplantation
- Trial name
- PIC-R (NCT03090828)
- Testing
- app-based therapeutic education, enhanced app-based therapeutic education
- Volunteers
- 1,600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Vasculopathy, Heart Transplant Failure
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients.
- Trial name
- NCT05485467
- Testing
- coronary CT angiography
- Where
- Slovenia
- Volunteers
- 55 people
- Sponsor
- University Medical Centre Ljubljana
Fanconi Anemia Complementation Group A, Fanconi Anemia
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
This is a long-term safety and efficacy follow-up study for subjects with Fanconi Anaemia Subtype A who have been treated with ex vivo gene therapy on the FANCOLEN-I trial.
- Trial name
- NCT04437771
- Testing
- Safety and efficacy assessments
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
End Stage Liver Disease
Pilot Study of the Liver Live Donor Champion Program
In this pilot study, investigators plan to enroll liver transplant candidates and a "Live Donor Champion" for an abridged two- or three-month program that provides education and advocacy training in order to expand access to live…
- Trial name
- LLDC (NCT03580629)
- Testing
- Liver Live Donor Champion Program
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in Kidney Transplant Recipients in India
To determine the safety of sirolimus tablets in renal allograft recipients in a postmarketing surveillance setting.
- Trial name
- NCT00195481
- Testing
- Rapamune
- Where
- 5 sites in India
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Congestive Heart Failure, Coronary Artery Disease
Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection
MyoCell™ implantation by epicardial injection during CABG surgery has the potential to add a new dimension to the management of post-infarct deterioration of cardiac function.
- Conditions
- Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
- Trial name
- NCT00050765
- Testing
- MyoCell™ Autologous Myoblasts
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Bioheart, Inc.
Liver Disease, Liver Neoplasms
Orthotopic Liver Transplantation Using a Living Donor
The purpose of this study is to: determine the safety of donor right hepatic lobectomy as a procedure to provide a liver graft for living donor liver transplantation.
- Trial name
- NCT00152607
- Testing
- donor right hepatic lobectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Anemia, Aplastic
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of…
- Trial name
- NCT00578266
- Testing
- Cyclophosphamide,Campath IH and TBI
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Renal Failure, Chronic
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
Chronic transplant rejection remains the main cause of late kidney graft loss. We showed previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10 responses demonstrated an extremely low risk of acute…
- Trial name
- NCT00150891
- Testing
- Kidney transplantation, cyclosporine A, tacrolimus
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Giessen
Transplant; Failure, Kidney
Effects of Sevoflurane and Desflurane on Treg
This prospective interventional study aims to compare sevoflurane and desflurane anesthetic agents on regulatory T cell (Treg) numbers and its cytokine production in patients undergoing Living Donor Kidney Transplant (LDKT).
- Trial name
- NCT02559297
- Testing
- Sevoflurane, Desflurane
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Liver Transplantation
Hemodynamic Measurements During Liver Transplantation
The purpose of the study is to determine if the less invasive monitors are as reliable for measuring heart function in patients undergoing liver transplantation as the more invasive pulmonary artery.
- Trial name
- OLT (NCT00682110)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.